http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10301658-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c3cd4efdf582a23a35a134a1de9b3e4b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-26 |
| filingDate | 2015-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e34754272b12f6acfa76fab914ead27 |
| publicationDate | 2019-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10301658-B2 |
| titleOfInvention | Method for in vivo production of glycosaminoglycans |
| abstract | The present invention relates to a method for in vivo production of glycosaminoglycans (GAG), by metabolic engineering in a genetically modified cell. In a method according to the invention, said cell is genetically modified in order to express the genes coding for the enzymes that are suitable for synthesizing GAG from an exogenous precursor, preferably internalized by the cell. According to one specific feature, the present invention relates to a method for producing chondroitin or heparosan in a genetically modified bacterial cell, from an exogenous beta-galactoside precursor, preferably internalized by the cell. According to another specific feature, the present invention relates to the use of an Escherichia coli cell comprising at least the genes glcA-T, kfoC, kfiD and wbpP for the production of chondroitin. According to yet another specific feature, the present invention relates to the use of an Escherichia coli cell comprising at least the genes glcA-T, kfiA, kfiB, kfiC and kfiD for the production of heparosan. The present invention also relates to the use of the obtained glycosaminoglycans by implementing a method according to the invention in order to prepare a drug, a food composition or a cosmetic product. |
| priorityDate | 2014-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.